Previous 10 | Next 10 |
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
BioCopy AG collaborates with Immatics (IMTX) in the field of characterization of T cell receptors (TCRs).TCRs and their interactions with peptide-HLA complexes (human leukocyte antigen) play a crucial role for the human immune system in the recognition of tumors, among other things. The goal ...
BioCopy AG and Immatics enter into a collaboration to characterize T cell receptor - peptide-HLA interactions PR Newswire BASEL, Switzerland and TÜBINGEN, Germany , July 7, 2021 /PRNewswire/ -- BioCopy AG announces a collaboration with Immatics N.V. (NAS...
Immatics N.V. (IMTX) has signed service agreements with Selexis SA and KBI Biopharma to advance the company's TCR bispecific program.Under the agreements, Selexis will utilize its SURE technology Platform and KBI will leverage its advanced analytics, process, for...
Tuebingen , Germany and Houston, Texas , May 26 , 2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, to...
Immatics (IMTX): Q1 GAAP EPS of -€0.34.Revenue of €7.4M (+5.1% Y/Y)Press Release For further details see: Immatics reports Q1 results
D ata update for ongoing ACTengine® IMA200 clinical trial series demonstrate d first anti-tumor activity in heavily pre-treated solid cancer patients during early phases of dose escalation Next ACTengine® data update for dose...
Immatics ’ second TCR Bispecific s program IMA402 demonstrate s t umor cell killing in vitro and complete regression s of established tumor s in a n in vivo tumor model ...
Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus. Their lead asset, tebentafusp, i...
VirTra (VTSI) +56% on Q4 results.Color Star Technology Co., Ltd. (CSCW) +56% as company to develop NFT.Performant Financial Corporation (PFMT) +26%.Monopar Therapeutics (MNPR) +18% on preclinical update of its uPA.Moleculin Biotech (MBRX) +18% on FDA's fast track desi...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...